Scaling Up the Value: BioLamina

Uppsala BIO has an important role to connect and contribute to the overall growth of Life Sciences, nationally and internationally, both for academic institutions and companies.
Since the beginning of Testa Center, Uppsala BIOs team has an external project coordinator role and has developed the application and selection process based on the BIO-X methodology.
Involved in the in-coaching process to evaluate and guide the actors to securing successful project execution in the center, Uppsala BIO has played an important part in the overall development of Testa Center and increased the overall value of the actors that use the facility. Read the success story about BioLamina.


Manufacturing proteins to support turning cells into any organ of the human body may seem like a movie scene, but BioLamina, a flourishing Swedish company makes it seem more real. Dedication, knowledge and the right environment are the necessary tools to achieve the goal of scaling up and growth. With that in mind, the team from BioLamina entered Testa Center.

Mission accomplished

The team from BioLamina came out acquiring a new educational level in bioprocessing, do-it-yourself and hands-on experience and increased overall value. One thing they haven’t anticipated is that they will even figure out how to design their own laboratory. They packed their equipment ready to leave, very happy with the outcome of their work at Testa.

“We came to Testa center with a 10 Liters scale process already developed to manufacture our product MX/CTG Laminin 521. We aimed to scale up the process to 40 L. Now we have designed a process that allows us to produce and process 40 Liters of harvest multiple times in a month, if necessary”, explains Parinith Sudhakar, an upstream scientist from BioLamina, who spent several months testing and scaling up at the facility.

Testa has passed the test

The future is bright for BioLamina and the next steps for the team is to validate the developed process in house at their own facility, to prepare them for commercial productions.
“The results that we have gotten from Testa makes way to consider scaling the process even further for e.g. to 200 L scale. Besides, we have many more isoforms of Laminins that are in the pipeline; the experience and results add to our strengths to execute our future projects. I don’t exclude the possibility to come back to Testa Center in the future” adds Parinith.
Increasing sales and customer demand had put Biolamina in a situation where production processes needed up-scaling in a quite short time frame. Therefore, it has been of paramount importance to be fast and efficient, and Testa has passed the test. Essential, according to BioLamina was the competence from the Testa team. Availability of competence was a key success factor in order to keep the tight timelines. Also, acquainting new skills and getting familiar with new equipment fast, was crucial to them.
“GE is one of the best in bioprocessing business. Learnings from here are great. There were many materials and consumables that we didn’t have knowledge of and the staff at Testa helped us in choosing and ordering the right materials that go into our application beforehand. This saved us a lot of time and we could focus more on the process” adds the scientist.

Upstream and downstream

Testa Center: Can you describe the upstream process at Testa Center?

Parinith Sudhakar: In upstream, for one of the unit operation in our scale-up design, we used Ready to Process Wave 25, that we got from Testa center. It was an excellent choice since we could run many small-scale studies to determine optimal operating settings before doing actual scale up. This unit operation simplified our scale-up process.

Testa Center: Was Testa Center’s team helpful?

Parinith Sudhakar: Even before I did these small-scale studies, I had taken up a few technical discussions with the upstream specialist at Testa center and a GE sales member to evaluate the feasibility of the idea. Also, some suggestions from their experience made us rule out certain types of materials/options which could contribute to poor process design. The discussions were very useful to go ahead with more confidence. This wouldn’t have been possible if we were to take these decisions by ourselves.

Testa Center: Did you have any help regarding the downstream process?

Parinith Sudhakar: Same thing applies to the downstream process. The downstream specialist at Testa had arranged a meeting between us and other experts from GE campus. This was even before we started to execute our plan. Hearing comments on our ideas from many experts reaffirmed our confidence.

The equipment

Testa has provided the essential instrument and consumables:

– XDM-50 and -100 mixer for loading preparation
– 3D bags
– ÄKTA pilot 600
– BPG100/500 column

Sanja Vasileva. Marketing & Communication. “Developing content, building stories and communicating them is what I am passionate about.”

Contact me
- 2019-06-25

Scaling Up the Value: BioLamina

Uppsala BIO has an important role to connect and contribute to the overall growth of Life Sciences, nationally and internationally, both for academic institutions and companies.
Since the beginning of Testa Center, Uppsala BIOs team has as an external project coordinator role and has developed the application and selection process based on the BIO-X methodology.


Helena Ströberg, Uppsala BIO - 2019-06-19

Breaking down the numbers 2017-2018

The overall goal of Uppsala BIO is to contribute to Upsala's vision of 70,000 new jobs in 2050. Of these, at least 3500 jobs will be created in the life science sector.


Kristin Hellman, Uppsala BIO - 2018-08-22

Uppsala BIO helps Testa Center off to a flying start

Process based on successful BIO-X methodology.


Kristian Sandberg, Director of DDD, SciLifeLab in Uppsala - 2018-08-21

How to bridge the ‘Valley of Death’

The SciLifeLab Drug Discovery Model.


Erik Forsberg, Uppsala BIO - 2018-06-15

“You can make a holding company profitable, but it takes a bit of luck.”

This autumn, Lars Jonsson, CEO of UU Holding since 1998, retires and hands over a very successful investment business to his successor. “UU Holding is nothing short of a success story,” writes Uppsala BIO’s Erik Forsberg. Lars Jonsson has proven that it is possible to make a holding company profitable.


Magnus Engevik, Uppsala BIO - 2018-05-21

Uppsala’s innovation support system works! Award-winning Kontigo Care is the latest proof.

“With its high costs and huge suffering for those affected as well as their relatives, alcohol abuse is one of our major social problems. Kontigo Care’s work on digital biomarkers is one of the most exciting things I’ve witnessed during my career,” writes Uppsala BIO Buiness Developer Magnus Engevik.


Margaretha Gadnell, Uppsala BIO - 2018-04-25

Spotlight Uppsala’s unique resource!

Uppsala’s life science industry is healthy and developing well. More than 100 life science companies can be found here and in 2016 they employed about 5000 people and had a combined turnover of approximately SEK 27 billion.


Christina Wass, Project leader, Innovation Akademiska - 2017-12-13

“What happens in Vegas stays in Vegas…”

During 52 hours, staff from the Academic Hospital, AbbVie, Bristol Myers-Squibb and Microsoft worked together to develop and test new ideas and models for early diagnosis and better treatment of cancer. Now the experiences of Sweden's first “Innovation Race” can be summed up.


Lovisa Case - 2017-11-07

50 years of excellence – it all started with a collaboration between academia and industry!

2017 marks the 50 year anniversary of the RAST-method. Learn about the history and see how Uppsala BIO and UU Innovation are addressing future challenges in asthma and allergy diagnostics.


Johan Gómez de la Torre - 2017-10-25

Sweden needs new regulations and ways for collaboration to stay ahead in healthcare and the life sciences

Challenges and opportunities for countries wanting to take a leading role in life sciences, with focus on the future role of Sweden, was the topic of a seminar in May 2017. In our blog Johan Gómez de la Torre, Business Development Manager, Stockholm Science City digest the report.


Anna Ridderstad Wollberg - 2017-10-16

Call for proposals: A pull to transform inventions into innovations

How do we pull out the good ideas that may become new innovative products or treatments for the benefit of patients? Calls for project proposals may be the pull that is needed.


Madeleine Neil, Uppsala Health Summit - 2017-10-08

Uppsala Health Summit 2017: Time for the world to meet on Infectious Disease Threats  

10 – 11 October Uppsala Health Summit gathered 200 decision makers and experts from 30 different countries in a discussion about global threats from zoonotic infectious diseases. 


Karin Meyer, CEO, Swedish Pharmaceutical Society - 2017-10-02

EMA needs Sweden’s strong scientific environment

Karin Meyer, CEO, Swedish Pharmaceutical Society about what Sweden can offer the EMA and EU.


Margaretha Gadnell, Uppsala BIO - 2017-09-26

Check out EIT Health and its Uppsala activities

The purpose of EIT Health is to accelerate entrepreneurship and innovation for healthy living and active ageing in Europe.


Margareta Gadnell, Uppsala BIO - 2017-09-18

Fast-growing companies in Uppsala’s life science cluster

Between 2014 and 2015, the number of employees in this category increased by 11%. If we include 2013 as well, the increase is almost 20%.


Erik Forsberg, Uppsala BIO - 2017-08-28

Financial support and further action!

Our long-term goal is, as always, to contribute to growth by driving actions that complement those of the private and public sectors.


Annakarin Svenningsson, Uppsala BIO - 2017-08-15

Tough competition prior to relocation of EMA after Brexit

Among the arguments stressed in the Swedish application to convince other member states that Sweden and Stockholm is best suited to host the EMA, is the Swedish Medical Products Agency (MPA) in Uppsala.


- 2019-12-06


A visionary who wants to make a difference

Life Science is entering a new and exciting time, sometimes called the fourth industrial revolution. To meet these opportunities, the STUNS foundation has recruited Björn Arvidsson to fulfill the role of the new Managing director of the foundation's life science branch Uppsala BIO. Björn’s most recent engagement has been at the Swiss pharmaceutical and diagnostics giant Roche.